1. on invasive mechanical ventilation (either intubated or tracheostomized) 2. heart failure as the main cause of acute respiratory failure 3. on long-term oxygen or home mechanical ventilation 4. decompensated liver cirrhosis 5. immunosuppression (i.e., cancer on treatment, post-organ transplantation, hiv-positive, on immunosuppressant therapy) 6. on chronic steroid therapy or other immunomodulant therapy (e.g., azathioprine, methotrexate, mycophenolate, convalescent/hyperimmune plasma) 7. chronic renal failure with dialysis dependence 8. progressive neuro-muscular disorders 9. cognitively impaired, dementia or decompensated psychiatric disorder 10. quadriplegia/hemiplegia or quadriparesis/hemiparesis 11. do-not-resuscitate order 12. participating in other clinical trial including experimental compound with proved or expected activity against sars-cov-2 infection 13. any other condition that in the opinion of the investigator may significantly impact with patient's capability to comply with protocol intervention 14. refuse to participate in the study or absence of signed informed consent form.

1. on invasive mechanical ventilation (either intubated or tracheostomized) 2. heart failure as the main cause of acute respiratory failure 3. on long-term oxygen or home mechanical ventilation 4. decompensated liver cirrhosis 5. immunosuppression (i.e., cancer on treatment, post-organ transplantation, hiv-positive, on immunosuppressant therapy) 6. on chronic steroid therapy or other immunomodulant therapy (e.g., azathioprine, methotrexate, mycophenolate, convalescent/hyperimmune plasma) 7. chronic renal failure with dialysis dependence 8. progressive neuro-muscular disorders 9. cognitively impaired, dementia or decompensated psychiatric disorder 10. quadriplegia/hemiplegia or quadriparesis/hemiparesis 11. do-not-resuscitate order 12. participating in other clinical trial including experimental compound with proved or expected activity against sars-cov-2 infection 13. any other condition that in the opinion of the investigator may significantly impact with patient's capability to comply with protocol intervention 14. refuse to participate in the study or absence of signed informed consent form.

on invasive mechanical ventilation (either intubated or tracheostomized) heart failure as the main cause of acute respiratory failure on long-term oxygen or home mechanical ventilation decompensated liver cirrhosis immunosuppression (i.e., cancer on treatment, post-organ transplantation, hiv-positive, on immunosuppressant therapy) on chronic steroid therapy or other immunomodulant therapy (e.g., azathioprine, methotrexate, mycophenolate, convalescent/hyperimmune plasma) chronic renal failure with dialysis dependence progressive neuro-muscular disorders cognitively impaired, dementia or decompensated psychiatric disorder quadriplegia/hemiplegia or quadriparesis/hemiparesis do-not-resuscitate order participating in other clinical trial including experimental compound with proved or expected activity against sars-cov-2 infection any other condition that in the opinion of the investigator may significantly impact with patient's capability to comply with protocol intervention refuse to participate in the study or absence of signed informed consent form.

on invasive mechanical ventilation (either intubated or tracheostomized) heart failure as the main cause of acute respiratory failure on long-term oxygen or home mechanical ventilation decompensated liver cirrhosis immunosuppression (i.e., cancer on treatment, post-organ transplantation, hiv-positive, on immunosuppressant therapy) on chronic steroid therapy or other immunomodulant therapy (e.g., azathioprine, methotrexate, mycophenolate, convalescent/hyperimmune plasma) chronic renal failure with dialysis dependence progressive neuro-muscular disorders cognitively impaired, dementia or decompensated psychiatric disorder quadriplegia/hemiplegia or quadriparesis/hemiparesis do-not-resuscitate order participating in other clinical trial including experimental compound with proved or expected activity against sars-cov-2 infection any other condition that in the opinion of the investigator may significantly impact with patient's capability to comply with protocol intervention refuse to participate in the study or absence of signed informed consent form.

1. on invasive mechanical ventilation (either intubated or tracheostomized) 2. heart failure as the main cause of acute respiratory failure 3. on long-term oxygen or home mechanical ventilation 4. decompensated liver cirrhosis 5. immunosuppression (i.e., cancer on treatment, post-organ transplantation, hiv-positive, on immunosuppressant therapy) 6. on chronic steroid therapy or other immunomodulant therapy (e.g., azathioprine, methotrexate, mycophenolate, convalescent/hyperimmune plasma) 7. chronic renal failure with dialysis dependence 8. progressive neuro-muscular disorders 9. cognitively impaired, dementia or decompensated psychiatric disorder 10. quadriplegia/hemiplegia or quadriparesis/hemiparesis 11. do-not-resuscitate order 12. participating in other clinical trial including experimental compound with proved or expected activity against sars-cov-2 infection 13. any other condition that in the opinion of the investigator may significantly impact with patient's capability to comply with protocol intervention 14. refuse to participate in the study or absence of signed informed consent form.

1. on invasive mechanical ventilation (either intubated or tracheostomized) 2. heart failure as the main cause of acute respiratory failure 3. on long-term oxygen or home mechanical ventilation 4. decompensated liver cirrhosis 5. immunosuppression (i.e., cancer on treatment, post-organ transplantation, hiv-positive, on immunosuppressant therapy) 6. on chronic steroid therapy or other immunomodulant therapy (e.g., azathioprine, methotrexate, mycophenolate, convalescent/hyperimmune plasma) 7. chronic renal failure with dialysis dependence 8. progressive neuro-muscular disorders 9. cognitively impaired, dementia or decompensated psychiatric disorder 10. quadriplegia/hemiplegia or quadriparesis/hemiparesis 11. do-not-resuscitate order 12. participating in other clinical trial including experimental compound with proved or expected activity against sars-cov-2 infection 13. any other condition that in the opinion of the investigator may significantly impact with patient's capability to comply with protocol intervention 14. refuse to participate in the study or absence of signed informed consent form.

1. on invasive mechanical ventilation (either intubated or tracheostomized) 2. heart failure as the main cause of acute respiratory failure 3. on long-term oxygen or home mechanical ventilation 4. decompensated liver cirrhosis 5. immunosuppression (i.e., cancer on treatment, post-organ transplantation, hiv-positive, on immunosuppressant therapy) 6. chronic renal failure with dialysis dependence 7. progressive neuro-muscular disorders 8. cognitively impaired, dementia or decompensated psychiatric disorder 9. quadriplegia/hemiplegia or quadriparesis/hemiparesis 10. do-not-resuscitate order 11. previous or current use of remdesivir 12. participating in other clinical trial including experimental compound with proved or expected activity against sars-cov-2 infection 13. any other condition that in the opinion of the investigator may significantly impact with patient's capability to comply with protocol intervention

1. on invasive mechanical ventilation (either intubated or tracheostomized) 2. heart failure as the main cause of acute respiratory failure 3. on long-term oxygen or home mechanical ventilation 4. decompensated liver cirrhosis 5. immunosuppression (i.e., cancer on treatment, post-organ transplantation, hiv-positive, on immunosuppressant therapy) 6. chronic renal failure with dialysis dependence 7. progressive neuro-muscular disorders 8. cognitively impaired, dementia or decompensated psychiatric disorder 9. quadriplegia/hemiplegia or quadriparesis/hemiparesis 10. do-not-resuscitate order 11. previous or current use of remdesivir 12. participating in other clinical trial including experimental compound with proved or expected activity against sars-cov-2 infection 13. any other condition that in the opinion of the investigator may significantly impact with patient's capability to comply with protocol intervention